Standard Vape Forms New Subsidiary with Potential Covid19 Treatment

April 22, 2020 Locust Valley, New York

STANDARD VAPE FORMS NEW SUBSIDIARY WITH POTENTIAL COVID-19 TREATMENT

STANDARD VAPE CORPORATION (SVAP-OTC PINK) announced today that on April 14, 2020, SVAP had acquired Neo-Virucide, Inc. (NVI), a newly formed Wyoming corporation that owns an exclusive worldwide license on the use of a proprietary nanoparticle NanoNOx™ for treatment of microbial and viral infections.  NVI entered a related party contract with NMB Therapeutics, Inc. (NMB), the Worldwide Exclusive License and Product Development Agreement. This Agreement provides worldwide marketing rights to NanoNOx™, the proprietary nanoparticle upon which a United States Provisional Patent Application had been filed in November, 2019. While NanoNOx™ has several uses, NVI’s present focus is assisting NMB in gaining permission from the FDA or foreign agencies or testing locations to test NanoNOx™ in human trials as a means of delivering nitric oxide into deep lung tissue for the purpose of treating COVID-19. The relaxation of testing requirements for COVID-19 treatment under President Trump’s timely policies may make this goal more easily obtained.

It is believed that NanoNOx™ will act as a vasodilator in the lungs to promote better oxygenation to counter the respiratory effects of the viral infection in the lungs. To that end NMB has found a hospital clinic at a major U.S. university that may be willing to sponsor and investigate the use of NanoNOx™ in a clinical trial subject to formalizing that arrangement. The study is believed to unique among COVID-19 clinical tests in that it will be an outpatient study. NVI will update its disclosure when further developments with clinical testing occur.

Nitric Oxide in gaseous form is currently being tested as a respiratory vasodilator for COVID-19 therapy at, among other places, Massachusetts General Hospital. NVI believes that NanoNOx™ would provide a more convenient form for administering nitric oxide. Presently, nitric oxide inhalation sessions require about forty minutes a day using a tank. NanoNOx™ is taken in a powder form using a device somewhat similar to an asthma inhaler taking a minute two to three times a day and replacing the tank based inhalation system with an inhaler weighing a couple ounces.

NanoNOx™ may have other desirable applications including as an inhaled antimicrobial treatment for respiratory infections and precursor to other applications including a possible transdermal application for acne. Many, perhaps all, of these applications will require FDA clearance and will thus need significant funding for which no assurances can be made as to the availability of such financing. As noted by NVI President, Roger Fidler, “We are at the beginning of the use of a new molecule. If we are to develop its full potential for the myriad of uses which may exist there will be years of research and clinical testing ahead. Our first goal is to fund a $100,000 payment to NMB Therapeutics due in thirty days to lock in the worldwide license rights until first commercial sale or Phase 2 success, whichever comes first, then we owe NMB an additional $400,000 plus interest.” Thereafter there will be 8% royalties with minimums to be negotiated.

Legal Disclaimer

This release contains forward-looking statements within the meaning of Section 27a of the Securities Act of 1933, as amended and section 21e of the Securities and Exchange Act of 1934, as amended. Those statements include the intent, belief or current expectations of the company and its management team. Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management's plans and objectives for future operations. Some or all the events or results anticipated by these forward-looking statements may not occur. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Accomplishing the strategy described herein is significantly dependent upon numerous factors, many that are not in management's control.

Contact Information

Roger Fidler
Legal Counsel to SVAP

NVI President
(201) 220-8734
rfidler0099@aol.com